Health Blog : FDA Committee Won't Consider Controversial Avandia Study

Health Blog : FDA Committee Won't Consider Controversial Avandia Study: "Questions over whether GlaxoSmithKline’s diabetes drug Avandia contributes to heart-attack risk went from simmer to boil in May after the New England Journal of Medicine published online an analysis by the Cleveland Clinic’s Steven Nissen. He concluded that the drug was riskier than many had thought."